Cyclopharm logo

CYC - Cyclopharm Share Price

A$1.28 0.0  1.6%

Last Trade - 2:18am

Sector
Healthcare
Size
Micro Cap
Market Cap £46.6m
Enterprise Value £46.8m
Revenue £7.33m
Position in Universe 707th / 1841
Bullish
Bearish
Unlock CYC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CYC Revenue Unlock CYC Revenue

Net Income

CYC Net Income Unlock CYC Revenue

Normalised EPS

CYC Normalised EPS Unlock CYC Revenue

PE Ratio Range

CYC PE Ratio Range Unlock CYC Revenue

Dividend Yield Range

CYC Dividend Yield Range Unlock CYC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CYC EPS Forecasts Unlock CYC Revenue
Profile Summary

Cyclopharm Limited is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. The Company operates in two business segments: Technegas segment and Molecular imaging segment. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals used by physicians in the detection of cancer, neurological disorders and cardiac diseases. The Company offers Technegas for lung imaging, and Molecular Imaging/Positron Emission Tomography radiopharmaceuticals, which are used in cancer, brain and cardiac imaging. The Company formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Company's Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated October 31, 2005
Public Since January 18, 2007
No. of Shareholders: n/a
No. of Employees: 36
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 68,898,873
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address U 4 1 the Crescent, MELBOURNE, 2208, Australia
Web http://www.cyclopharm.com.au/
Phone +61 2 95410411
Auditors Nexia Sydney Audit Pty Limited
CYC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CYC
Upcoming Events for CYC
Similar to CYC
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.